My pronouns are he/him (in German er), and I was born in the 76th year of the last century.
I'm extremely single-mindedly all about Emhyr/Geralt of The Witcher books and games, and that's what I write.
I'm neither bi nor into women and hence evil, reticent, incorrigable and not enlightened.
I sometimes also like other things, such as Mo Xiang Tong Xiu's danmei Mo Dao Zu Shi (#MDZS) which has been made into The Untamed (#CQL) - the show isn't my thing due to the changes to the book but I enjoy looking at pictures, gifs and BTS of it.
I also feel quite entertained by The Scum Villain's Self-Serving System (#SVSSS) by the same author but mainly on the cracky side.
Sometimes I post Nirvana in Fire things, which is the best TV there ever was, and I also play some games sometimes (The Witcher 3, Skyrim, Tails of Iron, Cult of the Lamb, Animal Crossing...)
here's where you can find my fics on the net:
AntimonySchnuck on Ao3
I've also uploaded my fics as backup on Pillowfort
and on Dreamwidth
but imho reading is better on Ao3 - also you can leave me kudos there :D
i think we should be ridiculing them more for this. you don't get to try and go all "queer website" when your staff likes to go on nuking sprees targeting the trans fem users
would be remiss not to mention that the rainbow notably straight up just removed the trans flag colors from it. like theyâre gone. itâs the progress flag minus the trans flag colors.
KrĂźmel insisted on lying in his spot this morning, despite my mom's duvet being in his spot, too, folded in a big heap, because it's too hot for duvets right now.
So there he was lying tilted in a 40° angle, holding himself up with the claws. (Minzbari, for the German B5 connoisseur.)
Why don't you go somewhere more comfy, I asked, and he clearly communicated via facial expression that this is HIS SPOT.
people in fiction are always making plans like "how about tuesday?" and then leaving without elaborating. what time? where? do you even have each other's numbers? deeply stressful
trying to create an ebay account to sell smthn and tell me why I can't use my REAL LEGAL LAST NAME because it includes "dick" which ebay considers offensive
BUT THEN IN THEIR MISREPRESENTATION POLICY THEY SAY YOU CAN'T COLLECT MONEY TO A BANK ACCOUNT THAT'S NOT IN YOUR BUSINESS OR LEGAL NAME. BUT MY LEGAL NAME INCLUDES DICK, WHICH YOU CONSIDER OFFENSIVE.
the sanitization of the internet is so fucking stupid we live in the stupidest time
For millions of people managing type 2 diabetes, mornings begin the same way â a needle, a dose, and a quiet mental note to do it all again
"For millions of people managing type 2 diabetes, mornings begin the same way â a needle, a dose, and a quiet mental note to do it all again tomorrow.
That routine just changed.
On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.
This is not a minor update to an existing drug.
It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.
Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.
That means reducing from 365 injections a year down to just 52.
For anyone who has ever felt the weight of that daily ritual â the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help â this approval represents something much bigger than a dosing schedule.
It represents relief.
How the Drug Actually Works
Understanding why this injection lasts a full week requires a quick look inside the body.
Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.
Awiqli works differently.
Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.
This attachment creates a slow-release reservoir.
Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock...
The FDA reviewed and ultimately declined to approve it for people with type 1 diabetes, citing concerns about a modestly increased risk of hypoglycemia in that population specifically.
Some regulatory agencies in other countries, including the European Union, Canada, Australia, and Japan, have approved Awiqli for both type 1 and type 2 diabetes, but for now the U.S. approval is limited to type 2...
What Comes Next
Awiqli is not standing alone in this space for long.
Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.
If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patientâs health profile, insurance coverage, and individual response.
The broader direction of travel in diabetes care is unmistakable.
Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise...
A Small Shot With Large Implications
It is easy to look at a once-weekly injection and see only a scheduling change.
But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.
Diabetes management has always asked a lot of people.
It asks for daily vigilance, daily discipline, and a daily willingness to confront oneâs own condition, sometimes in uncomfortable or inconvenient circumstances.
Anything that reduces that load, without reducing the quality of care, is worth taking seriously.
For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a personâs life.
That is the real significance of what the FDA approved on March 26, 2026.
Not just a new drug.
A new way of keeping people healthy, one week at a time."
